Hamburg - Delayed Quote EUR

Sanofi SA (SNW.HM)

91.01

+0.93

+(1.03%)

As of 8:01:14 AM GMT+2. Market Open.

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1 movement. The partnership, announced on T1D Day, comes as the Screen For Type 1 movement strives to expand diabetes education nationwide, raising awareness of the benefits of early risk detection.

PR Newswire yesterday

SNY

SNYNF
0.00%
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthmaItepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage r

GlobeNewswire 2 days ago

SNY

SNYNF
0.00%
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O

Bloomberg 7 days ago

BMY

CELG-RT

PFE
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priorit

GlobeNewswire 8 days ago

SNY

SNYNF
0.00%
Tariffs Stoke Fears That Hung Debt Will Return

(Bloomberg) -- Deals in leveraged finance have stalled, and markets have been upended, raising the possibility that banks might once again get stuck with debt they’ve committed for acquisitions.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsWhat Would ‘Transportation Abundance’ Look

Bloomberg 11 days ago

C

WW

SNY
Sanofi: Information concerning the total number of voting rights and shares - February 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,467,152,142Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 13 days ago

SNY

SNYNF
0.00%
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related diseaseRilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kina

GlobeNewswire 14 days ago

SNY

SNYNF
0.00%
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringeUnique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia Paris, March 28, 2025. The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-low

GlobeNewswire 19 days ago

SNY

SNYNF
0.00%
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophilsApproval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan

GlobeNewswire 20 days ago

SNY

SNYNF
0.00%
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and

GlobeNewswire 20 days ago

REGN

SNY

SNYNF
0.00%
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertilityA phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming days Paris, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection

GlobeNewswire 22 days ago

SNY

SNYNF
0.00%
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted br

GlobeNewswire 23 days ago

SNY

SNYNF
0.00%
Press Release: Availability of the Q1 2025 Aide mémoire

Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fir

GlobeNewswire 24 days ago

SNY

SNYNF
0.00%
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune systemAcquisition underpins path for Sanofi becoming leading immunology companySanofi to pay $600 million up front Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-020

GlobeNewswire 28 days ago

SNY

SNYNF
0.00%
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients a

PR Newswire last month

SNY

SNYNF
0.00%
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the Europ

GlobeNewswire last month

REGN

SNY

SNYNF
0.00%
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying typ

GlobeNewswire last month

SNY

SNYNF
0.00%
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor plus 0.300%€650 million fixed rate notes, due March 2031, bearing interest at an annual rate of 2.750%. The notes are being issued off the company's Euro Medium Term Note Program. Sanofi intends to use the net proceeds of the

GlobeNewswire last month

SNY

SNYNF
0.00%
What Trump's next batch of tariffs could mean for pharma industry

The Trump administration has hinted at new tariffs that could impose a 25% tax on all pharmaceutical imports. Yahoo Finance senior health reporter Anjalee Khemlani joins the Morning Brief team in assessing how these policies could hit top companies. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video last month

SNY

SNYNF
0.00%
AZN
Novavax reports large quarterly revenue declines, rethinks its strategic direction

Novavax closed up the day it reported a pivot in direction.

Yahoo Finance last month

SNY

SNYNF
0.00%
NONOF

Performance Overview

Return	SNW.HM	CAC 40 (^FCHI)
YTD	-2.06%	-0.69%
1-Year	+9.24%	-8.16%
3-Year	-1.01%	+11.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi SA (SNW.HM)

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tariffs Stoke Fears That Hung Debt Will Return

Sanofi: Information concerning the total number of voting rights and shares - February 2025

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

What Trump's next batch of tariffs could mean for pharma industry

Novavax reports large quarterly revenue declines, rethinks its strategic direction

Performance Overview